{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:04:30Z","timestamp":1786118670895,"version":"build-2736575974"},"reference-count":65,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1097\/mol.0b013e32821f603b","type":"journal-article","created":{"date-parts":[[2007,7,10]],"date-time":"2007-07-10T04:03:32Z","timestamp":1184040212000},"page":"421-426","source":"Crossref","is-referenced-by-count":17,"title":["New targets of high-density lipoprotein therapy"],"prefix":"10.1097","volume":"18","author":[{"given":"Stephen J","family":"Nicholls","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210205","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"R2-8-20210205","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study","volume":"62","author":"Gordon","year":"1977","journal-title":"Am J Med"},{"key":"R3-8-20210205","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1172\/JCI114558","article-title":"Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit","volume":"85","author":"Badimon","year":"1990","journal-title":"J Clin Invest"},{"key":"R4-8-20210205","first-page":"455","article-title":"High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits","volume":"60","author":"Badimon","year":"1989","journal-title":"Lab Invest"},{"key":"R5-8-20210205","doi-asserted-by":"crossref","first-page":"9607","DOI":"10.1073\/pnas.91.20.9607","article-title":"Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse","volume":"91","author":"Plump","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R6-8-20210205","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/353265a0","article-title":"Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI","volume":"353","author":"Rubin","year":"1991","journal-title":"Nature"},{"key":"R7-8-20210205","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1161\/01.ATV.0000184760.95957.d6","article-title":"Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits","volume":"25","author":"Nicholls","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R8-8-20210205","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1161\/hc4501.098952","article-title":"Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content","volume":"104","author":"Rong","year":"2001","journal-title":"Circulation"},{"key":"R9-8-20210205","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/01.RES.0000146094.59640.13","article-title":"Antiinflammatory properties of HDL","volume":"95","author":"Barter","year":"2004","journal-title":"Circ Res"},{"key":"R10-8-20210205","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1161\/01.ATV.0000104029.74961.f5","article-title":"Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I","volume":"24","author":"Rye","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R11-8-20210205","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1161\/01.CIR.0000103624.14436.4B","article-title":"Inflammatory\/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment","volume":"108","author":"Ansell","year":"2003","journal-title":"Circulation"},{"key":"R12-8-20210205","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/01.CIR.103.18.2283","article-title":"High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection","volume":"103","author":"Van Lenten","year":"2001","journal-title":"Circulation"},{"key":"R13-8-20210205","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jacc.2006.04.080","article-title":"Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function","volume":"48","author":"Nicholls","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R14-8-20210205","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"R15-8-20210205","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"R16-8-20210205","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.297.5.499","article-title":"Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis","volume":"297","author":"Nicholls","year":"2007","journal-title":"JAMA"},{"key":"R17-8-20210205","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"R18-8-20210205","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"R19-8-20210205","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"R20-8-20210205","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study.","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"R21-8-20210205","doi-asserted-by":"crossref","first-page":"19N","DOI":"10.1016\/S0002-9149(01)02148-8","article-title":"Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial","volume":"88","author":"Robins","year":"2001","journal-title":"Am J Cardiol"},{"key":"R22-8-20210205","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/01.CIR.85.1.37","article-title":"Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment","volume":"85","author":"Manninen","year":"1992","journal-title":"Circulation"},{"key":"R23-8-20210205","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1161\/CIRCULATIONAHA.105.565135","article-title":"Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial","volume":"113","author":"Otvos","year":"2006","journal-title":"Circulation"},{"key":"R24-8-20210205","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"R25-8-20210205","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"R26-8-20210205","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1124\/mol.106.030833","article-title":"Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells","volume":"70","author":"Benyo","year":"2006","journal-title":"Mol Pharmacol"},{"key":"R27-8-20210205","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm824","article-title":"PUMA-G and HM74 are receptors for nicotinic acid and mediate its antilipolytic effect","volume":"9","author":"Tunaru","year":"2003","journal-title":"Nat Med"},{"key":"R28-8-20210205","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11883-006-0054-4","article-title":"Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases","volume":"8","author":"Calabresi","year":"2006","journal-title":"Curr Atheroscler Rep"},{"key":"R29-8-20210205","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/01.CIR.97.8.780","article-title":"Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice","volume":"97","author":"Shah","year":"1998","journal-title":"Circulation"},{"key":"R30-8-20210205","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1161\/hc2501.092494","article-title":"High-dose recombinant apolipoprotein A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice","volume":"103","author":"Shah","year":"2001","journal-title":"Circulation"},{"key":"R31-8-20210205","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"key":"R32-8-20210205","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jacc.2005.11.040","article-title":"Relationship between atheroma regression and change in lumen size following infusion of apolipoprotein A-I Milano","volume":"47","author":"Nicholls","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R33-8-20210205","doi-asserted-by":"crossref","first-page":"16307","DOI":"10.1021\/bi991246n","article-title":"Cell cholesterol efflux to reconstituted high-density lipoproteins containing the apolipoprotein A-IMilano dimer","volume":"38","author":"Calabresi","year":"1999","journal-title":"Biochemistry"},{"key":"R34-8-20210205","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1161\/01.CIR.0000159351.95399.50","article-title":"Reconstituted high density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits","volume":"111","author":"Nicholls","year":"2005","journal-title":"Circulation"},{"key":"R35-8-20210205","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1567-5688(02)00047-8","article-title":"Reverse cholesterol transport in man: promotion of fecal steroid excretion by infusion of reconstituted HDL","volume":"3","author":"Angelin","year":"2002","journal-title":"Atheroscler Suppl"},{"key":"R36-8-20210205","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1161\/01.CIR.0000013424.28206.8F","article-title":"High-density lipoprotein restores endothelial function in hypercholesterolemic men","volume":"105","author":"Spieker","year":"2002","journal-title":"Circulation"},{"key":"R37-8-20210205","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1161\/01.CIR.0000070934.69310.1A","article-title":"Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein","volume":"107","author":"Bisoendial","year":"2003","journal-title":"Circulation"},{"key":"R38-8-20210205","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1161\/01.ATV.17.10.2132","article-title":"Large versus small unilamellar vesicles mediate reverse cholesterol transport in vivo into two distinct hepatic metabolic pools. Implications for the treatment of atherosclerosis","volume":"17","author":"Rodrigueza","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R39-8-20210205","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0005-2736(97)00198-3","article-title":"Cholesterol mobilization and regression of atheroma in cholesterol-fed rabbits induced by large unilamellar vesicles","volume":"1368","author":"Rodrigueza","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"R40-8-20210205","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1194\/jlr.M400438-JLR200","article-title":"Phosphatidylinositol increases HDL-C levels in humans","volume":"46","author":"Burgess","year":"2005","journal-title":"J Lipid Res"},{"key":"R41-8-20210205","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/01.CIR.0000089375.60050.35","article-title":"Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice","volume":"108","author":"Navab","year":"2003","journal-title":"Circulation"},{"key":"R42-8-20210205","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0022-2275(20)33434-9","article-title":"Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression","volume":"41","author":"Baker","year":"2000","journal-title":"J Lipid Res"},{"key":"R43-8-20210205","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.1074\/jbc.270.11.5882","article-title":"The effect of high density lipoprotein phospholipid acyl chain composition on the efflux of cellular free cholesterol","volume":"270","author":"Davidson","year":"1995","journal-title":"J Biol Chem"},{"key":"R44-8-20210205","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.ahj.2004.04.027","article-title":"Focus on high-density lipoproteins in reducing cardiovascular risk","volume":"148","author":"Brewer","year":"2004","journal-title":"Am Heart J"},{"key":"R45-8-20210205","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa071359","article-title":"Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia","volume":"356","author":"Kastelein","year":"2007","journal-title":"N Engl J Med"},{"key":"R46-8-20210205","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa070635","article-title":"Effect of torcetrapib on the progression of coronary atherosclerosis","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"R47-8-20210205","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/35018119","article-title":"A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits","volume":"406","author":"Okamoto","year":"2000","journal-title":"Nature"},{"key":"R48-8-20210205","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1161\/01.CIR.0000015857.31889.7B","article-title":"Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study","volume":"105","author":"de Grooth","year":"2002","journal-title":"Circulation"},{"key":"R49-8-20210205","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1161\/01.ATV.20.9.2106","article-title":"Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis","volume":"20","author":"Rittershaus","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R50-8-20210205","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0021-9150(03)00137-0","article-title":"The safety and immunogenicity of a CETP vaccine in healthy adults","volume":"169","author":"Davidson","year":"2003","journal-title":"Atherosclerosis"},{"key":"R51-8-20210205","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/7766","article-title":"A novel endothelial-derived lipase that modulates HDL metabolism","volume":"21","author":"Jaye","year":"1999","journal-title":"Nat Genet"},{"key":"R52-8-20210205","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1161\/01.RES.0000170946.56981.5c","article-title":"New insights into the regulation of HDL metabolism and reverse cholesterol transport","volume":"96","author":"Lewis","year":"2005","journal-title":"Circ Res"},{"key":"R53-8-20210205","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1161\/01.CIR.0000092889.24713.DC","article-title":"Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial lipase","volume":"108","author":"Maugeais","year":"2003","journal-title":"Circulation"},{"key":"R54-8-20210205","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1172\/JCI16146","article-title":"Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo","volume":"111","author":"Jin","year":"2003","journal-title":"J Clin Invest"},{"key":"R55-8-20210205","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1161\/01.CIR.0000028423.07623.6A","article-title":"Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol","volume":"106","author":"deLemos","year":"2002","journal-title":"Circulation"},{"key":"R56-8-20210205","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1371\/journal.pmed.0030022","article-title":"Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis","volume":"3","author":"Badellino","year":"2006","journal-title":"PLoS Med"},{"issue":"suppl","key":"R57-8-20210205","doi-asserted-by":"crossref","first-page":"24N","DOI":"10.1016\/S0002-9149(01)02149-X","article-title":"Peroxisome proliferator-activated receptor-\u03b1 activation and high-density lipoprotein metabolism","volume":"88","author":"Fruchart","year":"2001","journal-title":"Am J Cardiol"},{"key":"R58-8-20210205","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11883-000-0067-3","article-title":"Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms","volume":"2","author":"Plutzky","year":"2000","journal-title":"Curr Atheroscler Rep"},{"key":"R59-8-20210205","doi-asserted-by":"crossref","first-page":"9774","DOI":"10.1073\/pnas.0403506101","article-title":"ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins","volume":"101","author":"Wang","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R60-8-20210205","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1073\/pnas.112059299","article-title":"Synthetic LXR ligand inhibits the development of atherosclerosis in mice","volume":"99","author":"Joseph","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R61-8-20210205","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.105.560177","article-title":"Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo","volume":"113","author":"Naik","year":"2006","journal-title":"Circulation"},{"key":"R62-8-20210205","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1194\/jlr.R400010-JLR200","article-title":"PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis","volume":"45","author":"Li","year":"2004","journal-title":"J Lipid Res"},{"key":"R63-8-20210205","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1161\/01.ATV.0000165694.39518.95","article-title":"Apolipoprotein A-I mimetic peptides","volume":"25","author":"Navab","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R64-8-20210205","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/ncpcardio0661","article-title":"Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention","volume":"3","author":"Navab","year":"2006","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"R65-8-20210205","first-page":"II","article-title":"Oral administration of the apolipoprotein A-I mimetic peptide D-4F in humans with CHD improves anti-inflammatory function after a single dose","volume":"114","author":"Bloedon","year":"2006","journal-title":"Circulation"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MOL.0b013e32821f603b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:40:38Z","timestamp":1786034438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00041433-200708000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0b013e32821f603b","relation":{},"ISSN":["0957-9672"],"issn-type":[{"value":"0957-9672","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}